News Drug Development

Viewpoint Molecular Targeting(R) Presents Preclinical Data from VMT-

December 21, 2021 |

1 min read

Viewpoint Molecular Targeting, Inc. announced the presentation of preclinical data from its theranostic in development, VMT-

Optimized ²⁰³Pb/²¹²Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors
Preclinical data of VMT-

Preclinical

ACCESS Newswire

MORE ON THIS TOPIC

Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs

HIV

Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill

November 14, 2025

·

2 min read

·

Tristan Manalac

arrow down stock market investment global red technology background. Global economic slowdown and crisis. vector illustration fantastic technology.

RNA editing

Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal

November 13, 2025

·

3 min read

·

Annalee Armstrong

The factor that changes everything. A critical break. A sudden change in plans. A threat and a danger. Recover from the blow and get back on course. Severe stress. Withstand the blow.

Obesity

Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs

November 13, 2025

·

2 min read

·

Tristan Manalac

Collage image sketch of tired girl sleeping home nightmare monster in room isolated on drawing background.

Neuroscience

Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data

November 13, 2025

·

2 min read

·

Tristan Manalac